Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation
Rubén Martínez-Barricarte, … , Claire L. Harris, Santiago Rodríguez de Córdoba
Rubén Martínez-Barricarte, … , Claire L. Harris, Santiago Rodríguez de Córdoba
Published September 13, 2010
Citation Information: J Clin Invest. 2010;120(10):3702-3712. https://doi.org/10.1172/JCI43343.
View: Text | PDF
Research Article Nephrology Article has an altmetric score of 4

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

  • Text
  • PDF
Abstract

Dense deposit disease (DDD) is a severe renal disease characterized by accumulation of electron-dense material in the mesangium and glomerular basement membrane. Previously, DDD has been associated with deficiency of factor H (fH), a plasma regulator of the alternative pathway (AP) of complement activation, and studies in animal models have linked pathogenesis to the massive complement factor 3 (C3) activation caused by this deficiency. Here, we identified a unique DDD pedigree that associates disease with a mutation in the C3 gene. Mutant C3923ΔDG, which lacks 2 amino acids, could not be cleaved to C3b by the AP C3-convertase and was therefore the predominant circulating C3 protein in the patients. However, upon activation to C3b by proteases, or to C3(H2O) by spontaneous thioester hydrolysis, C3923ΔDG generated an active AP C3-convertase that was regulated normally by decay accelerating factor (DAF) but was resistant to decay by fH. Moreover, activated C3b923ΔDG and C3(H2O)923ΔDG were resistant to proteolysis by factor I (fI) in the presence of fH, but were efficiently inactivated in the presence of membrane cofactor protein (MCP). These characteristics cause a fluid phase–restricted AP dysregulation in the patients that continuously activated and consumed C3 produced by the normal C3 allele. These findings expose structural requirements in C3 that are critical for recognition of the substrate C3 by the AP C3-convertase and for the regulatory activities of fH, DAF, and MCP, all of which have implications for therapeutic developments.

Authors

Rubén Martínez-Barricarte, Meike Heurich, Francisco Valdes-Cañedo, Eduardo Vazquez-Martul, Eva Torreira, Tamara Montes, Agustín Tortajada, Sheila Pinto, Margarita Lopez-Trascasa, B. Paul Morgan, Oscar Llorca, Claire L. Harris, Santiago Rodríguez de Córdoba

×

Figure 1

Histology, immunofluorescence, and EM findings.

Options: View larger image (or click on image) Download as PowerPoint
Histology, immunofluorescence, and EM findings.
The first kidney biopsy ...
The first kidney biopsy in GN28 was performed in 1985. Although there was considerable variation in glomerular changes, there was remarkable similarity in the light, immunofluorescence, and ultrastructural findings in the original kidney biopsy and 2 allograft biopsies of GN28 and the kidney biopsies from III-1 and III-2. The characteristic histological lesion consisted of segmental mesangial hypercellularity with thickened, eosinophil-rich segments of basement membrane (A and B, arrows). The affected glomerular segments were PAS positive and reacted to trichrome stain (D, arrow). The affected tufts showed hypercellularity, leukocyte infiltration, and endothelial swelling. The mesangium showed variable expansion, matrix accumulation, and a lobular pattern (C and D, arrows). The main immunofluorescence findings were prominent and diffuse C3 deposits, granular and nodular in some glomerular areas (G and J). Mild deposits of C1q, IgA, and IgM were also associated with these deposits (not shown). All biopsies showed similar ultrastructural alterations consisting of a ribbon-like, osmiophilic deposit present in the GBM (E and I, red arrows). These deposits occasionally showed signs of dissolution with translucent areas (F, red arrows). The mesangial areas showed increased mesangial matrix with electron-dense deposits (H and I, yellow arrows). Original magnification: ×400 (A, B, G, and J); ×500 (C and D); ×2,200 (E and F); ×5,500 (H); ×7,800 (I). Patient number is indicated within each panel.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Highlighted by 1 platforms
Referenced in 1 clinical guideline sources
87 readers on Mendeley
See more details